Site Map
Pages
- About Clinical Trials
- Careers
- Company
- Company Sample
- Contact
- Cookie Policy
- Dr Austin Duffy, MD
- Dr Agustin Penedo, MD
- Dr Amita Patnaik
- Dr André Mansinho, MD
- Dr Andrew Sochacki, MD
- Dr Bernard Doger, MD, PhD
- Dr Daniel Morillo, MD
- Dr Drew W. Rasco, MD
- Dr Emiliano Calvo, MD, PhD
- Dr Gala Vega, MD
- Dr Geraldine O’Sullivan Coyne, MD, MRCPI, PhD
- Dr Irene Moreno, MD
- Dr Justin A. Call, MD
- Dr Kyriakos P. Papadopoulos
- Dr Leigh M. Seamon, DO, MPH, FACOG, FACS
- Dr Manish R. Sharma, MD
- Dr Manuel Pedregal, MD
- Dr Maria De Miguel, MD, PhD
- Dr Muralidhar Beeram, MD, MBBS
- Dr Nehal J. Lakhani, MD, PhD
- Dr Sreenivasa R. Chandana, MD, PhD
- Dr Tatiana Hernández Guerrero, MD
- Dr Victor Moreno, MD, PhD
- Dr William B. McKean, MD, PhD
- Early Phase
- Events
- Explore Clinical Trials
- Home
- Hospitals & Oncology Practices
- Leadership
- Locations
- Message from the CEO
- Newsroom
- Patient Stories
- Pharma
- Preclinical
- Principal Investigators
- Privacy Policy
- Products
- Publications
- Referring Physicians
- Research & Development
- Site Map
- START – Barcelona
- START – Dublin
- START – Lisbon
- START – Madrid – CIOCC
- START – Madrid – FJD
- START – Midwest
- START – Mountain Region
- START – San Antonio
Posts
- Tumor Models Boston Summit
- The START Center for Cancer Research Takes a Major Step Forward in its Mission to Bring the Hope of Cancer Research to Communities Globally
- T-cell–engaging Therapy for Solid Tumors
- T cell engagers in solid tumors kick the door down
- START Center to Open Lisbon, Portugal Location
- START Center Principal Investigators Contributed As Authors to 10 Posters and Abstracts at the Annual ESMO IO Meeting
- START Center for Cancer Care to Open New Locations in Lisbon and Dublin
- Society for Melanoma Research (SMR) Conference
- Society for Immunotherapy of Cancer (SITC) Conference
- Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRASG12C Mutation
- SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
- Scripps Melanoma Conference
- San Antonio Breast Cancer Symposium (SABCS)
- Safety, Pharmacodynamic, and Anti-Tumor Activity of SL-172154 As Monotherapy and in Combination with Azacitidine (AZA) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Patients (pts)
- Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial
- Predictive and therapeutic implications of a novel PLCy1/SHP2-driven mechanism of cetuximab resistance in metastatic colorectal cancer
- Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
- Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
- Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes
- Pembrolizumab for the treatment of non-small-cell lung cancer
- Patient-specific comorbidities as prognostic variables for survival in myelofibrosis
- New designs in early clinical drug development
- International Association for the Study of Lung Cancer (IASLC) Conference
- Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study
- Increased vulnerability of clinical research units during the COVID-19 crisis and their protection
- Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug-Drug Interaction Study
- Histology-agnostic drugs: A paradigm shift – A narrative review
- HERVs establish a distinct molecular subtype in stage II/III colorectal cancer with poor outcome
- First-in-human study with preclinical data of Bcl-2/Bcl-XL inhibitor Pelcitoclax in locally advanced or metastatic solid tumors
- First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors
- First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors
- First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy
- First-in human, First-in-class Phase I Trial of the Anti-CD47 Antibody Hu5F9 G4 in Patients with Advanced Cancers
- Fierce Clinical Summit
- Exelixis Announces Initial Dose-Escalation Results from the First-in-Human Phase I Trial Evaluating XL102 in Patients with Advanced Solid Tumors
- Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumors (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study
- European Society for Medical Oncology (ESMO) Congress 2024
- EHA 2024 Congress
- Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors
- Drug Information Association Global Annual Meeting 2024
- Dr. Patnaik shares her perspectives on START’s pivotal role in the development of new cancer drugs
- Dr. Emiliano Calvo Leads the Discussion of Next Generation Immunotherapy at ASCO 2023
- Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule
- Crystal structure of Spot 14, a modulator of fatty acid synthesis
- Combination Immunotherapy With IDO Inhibitors: Defining a Future Through Biomarker-Guided Patient Selection
- Co-targeting RANK pathway treats and prevents acquired resistance to CDK4/6 inhibitors in luminal breast cancer
- Characterization of in vitro and in vivo metabolic pathways of the investigational anticancer agent,2-methoxyestradiol
- CDK9 INHIBITORS: a promising combination partner in the treatment of hematological malignancies
- Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody
- BIO 2024 Convention
- Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)
- Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- An Interview with Dr. Drew Rasco: The Basics of Phase I Clinical Trials
- An analysis of genetic targets for guiding clinical management of follicular lymphoma
- American Urological Association (AUA) Conference
- American Society of Hematology (ASH) Annual Meeting
- American Society of Colon & Rectal Surgeons (ASCRS) Conference
- American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
- Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia
- A time to build and a time to burn: glucose metabolism for every season.
- A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors
- A Phase 1, First-in-Human, Dose-Escalation Study of MGD024, a CD123 x CD3 Bispecific Dart® Molecule, in Patients with Relapsed or Refractory CD123-Positive (+) Hematologic Malignancies
- A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors
- A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors
- A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (PODIUM-101)
- A First-in-Human Phase 1 Study of ABBV-525, a Small-Molecule MALT1 Inhibitor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma